NDATOPICAL, VAGINALCREAM, TABLET
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
3/8 — Basic
GYNE-LOTRIMIN 3 COMBINATION PACK (clotrimazole) by Bayer is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and malassezia furfur . First approved in 1996.
Drug data last refreshed 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GYNE-LOTRIMIN 3 COMBINATION PACK is a topical and vaginal cream/tablet formulation of clotrimazole, a broad-spectrum antifungal agent that disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis. It is indicated for vulvovaginal candidiasis, oral candidiasis, and other candida infections.
LOE Approaching
As LOE approaches, commercial teams are likely right-sizing and transitioning resources; expect consolidation of brand support and possible role elimination or reassignment within 12-24 months.
Mechanism of Action
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur . The primary action of clotrimzole is against dividing and growing organisms. In vitro ,…
Worked on GYNE-LOTRIMIN 3 COMBINATION PACK at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.